Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00185887
First received: September 12, 2005
Last updated: March 4, 2011
Last verified: March 2011

September 12, 2005
March 4, 2011
October 2003
July 2006   (final data collection date for primary outcome measure)
resolution of abnormal fetal heart tracing [ Time Frame: Administration of study medication to resolution of abnormal fetal heart tracing or operative delivery. ] [ Designated as safety issue: Yes ]
resolution of abnormal fetal heart tracing
Complete list of historical versions of study NCT00185887 on ClinicalTrials.gov Archive Site
  • cesarean section rate [ Time Frame: Data analysis ] [ Designated as safety issue: No ]
  • operative vaginal delivery rate [ Time Frame: Data analysis ] [ Designated as safety issue: No ]
  • neonatal outcomes [ Time Frame: time of delivery to time of discharge ] [ Designated as safety issue: No ]
  • cesarean section rate
  • operative vaginal delivery rate
  • neonatal outcomes
Not Provided
Not Provided
 
Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation
Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation

To compare nitroglycerin and terbutaline for intrapartum fetal heart rate resuscitation

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Fetal Distress
Drug: Terbutaline
Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
  • Active Comparator: Terbutaline
    Intervention: Drug: Terbutaline
  • Active Comparator: Nitroglycerine
    Intervention: Drug: Terbutaline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
110
October 2007
July 2006   (final data collection date for primary outcome measure)

Inclusion Criteria::

  • nonreassuring fetal heart rate tracing

Exclusion Criteria:- maternal cardiac disease, placental abruption, intrauterine growth restriction, prior cesarean section

Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00185887
79504
Not Provided
Yasser Yehia El-Sayed, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: Yasser Yehia El-Sayed Stanford University
Stanford University
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP